echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Bladder cancer is heavy! EU approves Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!

    Bladder cancer is heavy! EU approves Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!

    • Last Update: 2021-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bavencio belongs to PD-(L)1 oncology immunotherapy, a high-profile type of tumor immunotherapy designed to use the body's own immune system to fight cancer and have the potential to treat multiple types of tumors by blocking the PD-1/PD-L1 signaling path.
    Bavencio has been shown in preclinical models to be able to participate in both adaptive and congenital immune functions.
    Bavencio has been shown to release inhibition of T-cell-mediated anti-tumor immune responses in preclinical models by blocking the interaction between PD-L1 and PD-1 receptors.
    Pfizer signed a $2.85 billion deal with Merck in November 2014 to enter the PD-(L)1 field.
    , the two sides are currently advancing the JAVELIN Clinical Development Program, which involves more than 15 different types of tumors and more than 10,000 patients.
    In addition to stomach/gastroesophageal junction adenocarcinoma, these types of tumors include: ovarian cancer, breast cancer, head and neck cancer, Merkel cell carcinoma, non-small cell lung cancer, renal cell carcinoma and urethra cancer.
    () Original source: European Commission approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.